Knör Sebastian, Khrenov Alexey V, Laufer Burkhardt, Saenko Evgueni L, Hauser Charlotte A E, Kessler Horst
Center of Integrated Protein Science Munich, Department Chemie, Lehrstuhl II für Organische Chemie, Technische Universität München, Lichtenbergstrasse 4, Garching D-85747, Germany.
J Med Chem. 2007 Sep 6;50(18):4329-39. doi: 10.1021/jm070304x. Epub 2007 Aug 11.
Hemophilia A, one of the most severe bleeding disorders, results from an inherited deficiency of factor VIII (FVIII) function. Treatment by injection of FVIII has been a common procedure for decades. Nevertheless, the production and purification of FVIII remains a challenging task. Current procedures using immunoaffinity chromatography are expensive and suffer from the instability of the applied antibody ligands, which elute along with the product and contaminate it. Recently, FVIII was purified by use of octapeptide ligands, but their low protease-resistance limits their application. We here report the systematic rational and combinatorial optimization procedure that allowed us to transfer the octapeptide ligands into a small peptidomimetic. This compound is the smallest ligand known for separation of such a large protein (330 kDa). It not only binds and purifies FVIII with high efficiency but also is stable, protease-resistant, and cheap to produce in preparative scale. Hence it offers a valuable alternative to antibody-based purification procedures.
甲型血友病是最严重的出血性疾病之一,由遗传性凝血因子VIII(FVIII)功能缺陷引起。几十年来,注射FVIII一直是常见的治疗方法。然而,FVIII的生产和纯化仍然是一项具有挑战性的任务。目前使用免疫亲和色谱的方法成本高昂,且所用抗体配体不稳定,会与产物一起洗脱并污染产物。最近,人们使用八肽配体纯化FVIII,但它们的低蛋白酶抗性限制了其应用。我们在此报告了系统的合理和组合优化程序,该程序使我们能够将八肽配体转化为一种小分子拟肽。这种化合物是已知用于分离如此大的蛋白质(330 kDa)的最小配体。它不仅能高效结合和纯化FVIII,而且稳定、抗蛋白酶,并且在制备规模上生产成本低廉。因此,它为基于抗体的纯化程序提供了一种有价值的替代方法。